Expanded Access Policy

Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial. Expanded access is a regulatory pathway that allows patients with serious or life-threatening conditions to receive an investigational treatment outside of a clinical trial when no comparable or satisfactory treatment options are available.

Remix Therapeutics is committed to bringing new medicines to patients with unmet needs as quickly and safely as possible. We understand that for patients with serious diseases, such as cancer, waiting for an approved treatment can be difficult. However, Remix Therapeutics does not currently offer expanded access to our investigational products. We believe participation in a clinical trial is the optimal way to access our investigational therapy, REM-422. This approach will allow thorough evaluation of REM-422 to determine whether the treatment is safe and effective and support regulatory approvals.

We encourage patients to talk with their doctors about treatment options which may include participation in a clinical trial. A list of Remix Therapeutics clinical trials can be found on our website and at www.clinicaltrials.gov. We may reevaluate the status of our Expanded Access Policy as development of our investigational products progresses. Remix Therapeutics reserves the right to revise this Expanded Access Policy at any time.

We encourage you to speak with your physician about options that may be right for you. For inquiries related to our clinical studies, feel free to contact us at info@remixtx.com.